- Home
- CHPT vs KURA Comparison
CHPT vs KURA Comparison
Compare CHPT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- KURA
- Stock Information
- Founded
- CHPT 2007
- KURA 2014
- Country
- CHPT United States
- KURA United States
- Employees
- CHPT N/A
- KURA N/A
- Industry
- CHPT Industrial Specialties
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHPT Consumer Discretionary
- KURA Health Care
- Exchange
- CHPT Nasdaq
- KURA Nasdaq
- Market Cap
- CHPT 468.9M
- KURA 492.9M
- IPO Year
- CHPT N/A
- KURA N/A
- Fundamental
- Price
- CHPT $0.62
- KURA $5.76
- Analyst Decision
- CHPT Hold
- KURA Strong Buy
- Analyst Count
- CHPT 10
- KURA 11
- Target Price
- CHPT $1.58
- KURA $23.89
- AVG Volume (30 Days)
- CHPT 7.4M
- KURA 1.5M
- Earning Date
- CHPT 06-04-2025
- KURA 05-01-2025
- Dividend Yield
- CHPT N/A
- KURA N/A
- EPS Growth
- CHPT N/A
- KURA N/A
- EPS
- CHPT N/A
- KURA N/A
- Revenue
- CHPT $417,083,000.00
- KURA $67,991,000.00
- Revenue This Year
- CHPT $12.03
- KURA $44.32
- Revenue Next Year
- CHPT $26.85
- KURA $173.73
- P/E Ratio
- CHPT N/A
- KURA N/A
- Revenue Growth
- CHPT N/A
- KURA N/A
- 52 Week Low
- CHPT $0.51
- KURA $5.41
- 52 Week High
- CHPT $2.44
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- CHPT 49.33
- KURA 39.73
- Support Level
- CHPT $0.61
- KURA $5.48
- Resistance Level
- CHPT $0.63
- KURA $6.76
- Average True Range (ATR)
- CHPT 0.03
- KURA 0.34
- MACD
- CHPT 0.00
- KURA -0.02
- Stochastic Oscillator
- CHPT 31.28
- KURA 21.88
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.